

Basingstoke, Southampton and Winchester District Prescribing Committee (DPC)

Recommendations of the meeting of 12 February 2013

Supported or limited support, e.g. specialist recommendation/initiation

- **Eplerenone** -The Committee supported the availability of this product locally in adult patients with NYHA class II chronic heart failure and left ventricular dysfunction as an addition to optimal therapy.
- **Argatroban infusion** - The Committee supported the availability of this product locally as an option for the treatment of patients with heparin induced thrombocytopenia (HIT).
- **Acclidinium bromide dry powder inhaler** - The Committee supported the availability of this product locally. Acclidinium is a long-acting muscarinic antagonist (LAMA) used twice daily to relieve symptoms in COPD. Acclidinium has a lower acquisition cost than tiotropium.
- **Glycopyrronium bromide capsules for inhalation** – The Committee supported the availability of this product locally. It is a LAMA used once daily to relieve symptoms in COPD. Glycopyrronium has a lower acquisition cost than tiotropium.
- **Choice of LAMA** - The Committee advises that the choice of LAMA should be made taking into account patient preferences (such as inhaler device) and cost.
- **Flutiform (fluticasone / formoterol) inhalers** – The Committee supported the availability locally of the range of Flutiform inhalers as an option in the treatment of asthma.
- **Posaconazole** – The Committee recommended that posaconazole oral suspension should be classified as 'Red' and prescribing should remain with the specialist. Note voriconazole is already classified as 'Red'.

Not Supported currently

- **Dapagliflozin for the treatment of type 2 diabetes** - The Committee noted the NICE appraisal consultation document which states that NICE is minded to not recommend dapagliflozin in combination therapy to treat type 2 diabetes. The Committee is therefore unable to recommend the availability of dapagliflozin locally and awaits the final guidance from NICE.

Information / Reminders / Updates/ Safety Messages / NICE

- **Shared care guidelines** – The Committee discussed the most appropriate format (including length), content and methods for effective communication between specialists and GPs. Further work is underway to improve the usefulness and accessibility of guidelines locally.
- **Blood Glucose testing in people with type 1 diabetes** – The Committee noted the recent guidance from the Department of Health emphasising the need for regular testing in people with type 1 diabetes; <http://www.dh.gov.uk/health/2013/02/diabetes-test/>
- **Updated Wound Formulary** -The Committee approved the updated Wound Formulary. Copies will be distributed to practice nurses, community nurses and nursing homes.
- **Testing for heparin induced thrombocytopenia**- Following changes to national guidelines, University Hospital Southampton has changed their guidance so that routine testing for HIT is no longer required. Discharge information to GPs will be amended to reflect this change.